Ravoxertinib
Based on 51 publication(s) in Google Scholar
Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with an IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.74%
- CAS. Nr.: 1453848-26-4
- Formel: C21H18ClFN6O2
- Molecular Weight:440.86
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Ravoxertinib
More- Nature. 2025 Jan;637(8046):726-735. [Abstract]
- Cancer Cell. 2023 Jul 10;41(7):1345-1362.e9. [Abstract]
- Cell. 2018 Sep 20;175(1):186-199.e19. [Abstract]
- Nat Metab. 2022 Mar;4(3):374-388. [Abstract]
- Cell Mol Immunol. 2023 Feb;20(2):175-188. [Abstract]
- Nat Commun. 2026 Jan 21;17(1):1902. [Abstract]
- Nat Commun. 2023 Sep 30;14(1):6117. [Abstract]
- Sci Transl Med. 2021 Jan 27;13(578):eaba7308. [Abstract]
- Nucleic Acids Res. 2022 Apr 8;50(6):3096-3114. [Abstract]
- J Exp Clin Cancer Res. 2023 Jul 13;42(1):166. [Abstract]
- Cell Discov. 2026 Feb 24;12(1):13. [Abstract]
- Redox Biol. 2023 Sep:65:102825. [Abstract]
- Cell Rep Med. 2025 Feb 6:101970. [Abstract]
- Cell Death Dis. 2021 Dec 1;12(12):1123. [Abstract]
- Diabetes. 2021 Sep;70(9):2131-2146. [Abstract]
- Stem Cell Res Ther. 2025 Jul 1;16(1):337. [Abstract]
- Oncogene. 2021 Jul;40(30):4884-4893. [Abstract]
- Environ Pollut. 2021 Jan 1;268(Pt B):115748. [Abstract]
- Cell Rep. 2023 Sep 1;42(9):113048. [Abstract]
- Clin Transl Med. 2023 Aug;13(8):e1381. [Abstract]
- Neural Regen Res. 2023 Aug;18(8):1743-1749. [Abstract]
- Biochem Pharmacol. 2025 Jun 6:239:117032. [Abstract]
- Gastric Cancer. 2023 May;26(3):379-392. [Abstract]
- Cancer. 2020 Mar 15;126(6):1339-1350. [Abstract]
- Int Immunopharmacol. 2025 Nov 8;168(Pt 1):115798. [Abstract]
- Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):61. [Abstract]
- Zool Res. 2022 Jul 18;43(4):537-551. [Abstract]
- Mol Oncol. 2020 Nov;14(11):2894-2919. [Abstract]
- Cancers (Basel). 2022 Mar 19;14(6):1575. [Abstract]
- Cancers (Basel). 2022 May 19;14(10):2493. [Abstract]
- ACS Omega. 2023 May 23;8(22):19692-19704. [Abstract]
- J Cell Mol Med. 2020 Sep;24(17):10151-10165. [Abstract]
- iScience. 2024 Sep 12;27(10):110873. [Abstract]
- Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H580-H592. [Abstract]
- Proteomics. 2023 Aug;23(16):e2300041. [Abstract]
- J Pharmacol Exp Ther. 2020 Jul;374(1):104-112. [Abstract]
- Cell Signal. 2023 May:105:110607. [Abstract]
- Exp Mol Pathol. 2021 Feb;118:104587. [Abstract]
- Int J Med Sci. 2022 Jan 1;19(1):195-204. [Abstract]
- Pathol Res Pract. 2021 Dec:228:153682. [Abstract]
- Am J Cancer Res. 2020 Nov 1;10(11):3622-3643. [Abstract]
- J Cell Biochem. 2020 Mar;121(3):2343-2353. [Abstract]
- Toxicol In Vitro. 2020 Jun;65:104777. [Abstract]
- Reprod Sci. 2020 Feb;27(2):704-712. [Abstract]
- Biochem Biophys Rep. 2026 Jan 15:45:102454. [Abstract]
- Biochem Biophys Res Commun. 2021 May 21:554:63-70. [Abstract]
- Université de Lausanne. 2024 Feb 7.
- Indian J Pharm Sci. 2022.
- Universität Würzburg. 2021 Jan.
- ACS Comb Sci. 2019 Dec 9;21(12):805-816. [Abstract]
- Methods Mol Biol. 2018:1711:351-398. [Abstract]
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
RT-PCR
-
IP
-
RT-PCR
Biologische Aktivität
|
ERK2 3.1 nM (IC50) |
ERK1 6.1 nM (IC50) |
p-RSK 12 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
12 nM
Compound: 22; GDC-0994
|
Inhibition of ERK in PMA-stimulated human HepG2 cells assessed as inhibition of p90RSK serine-380 phosphorylation
Inhibition of ERK in PMA-stimulated human HepG2 cells assessed as inhibition of p90RSK serine-380 phosphorylation
|
[PMID: 27227380] |
Ravoxertinib (GDC-0994) also inhibits p90RSK with an IC50 of 12 nM[1].
Ravoxertinib (GDC-0994) is highly selective for ERK1 and ERK2, with biochemical potency of 1.1 nM and 0.3 nM, respectively[2].
Ravoxertinib (GDC0994; 50 nM, 0.5 μM, and 5 μM; 48 hours) decreases the viability of lung adenocarcinoma cell lines (A549, HCC827, HCC4006)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 1453848-26-4
-
Appearance Solid
-
Molecular Weight 440.86
-
Formel C21H18ClFN6O2
-
Color White to yellow
-
SMILES
O=C1C=C(C2=NC(NC3=CC=NN3C)=NC=C2)C=CN1[C@@H](C4=CC=C(Cl)C(F)=C4)CO
-
Synonyms
GDC-0994
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (51)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Jan;637(8046):726-735. PMID: 39537929
Ravoxertinib purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jan;637(8046):726-735. [Abstract]
Investigation of the signalling axis regulating LIF expression upon PDGF stimulation. Cells were treated with ERK inhibitor ravoxertinib (10 μM) for 24 h before cell lysis for total RNA extraction and measurement of LIF mRNA levels by real-time qPCR.
-
Cancer Cell
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. [Abstract]2023 Jul 10;41(7):1345-1362.e9. PMID: 37352863 -
Cell
2018 Sep 20;175(1):186-199.e19. PMID: 30220457 -
Nat Metab
MAPK signalling-induced phosphorylation and subcellular translocation of PDHE1α promotes tumour immune evasion. [Abstract]2022 Mar;4(3):374-388. PMID: 35315437 -
Cell Mol Immunol
β-adrenoreceptor-triggered PKA activation negatively regulates the innate antiviral response. [Abstract]2023 Feb;20(2):175-188. PMID: 36600052
Ravoxertinib purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Feb;20(2):175-188. [Abstract]
Effects of kinase inhibitors on ISO-triggered inhibition of SeV-induced transcription of the IFNB1 gene. THP1 cells were treated with the ERK inhibitor GDC-0994 (1 μM) for 1 h and then were treated with ISO (10 μM) and infected with SeV (MOI = 1). Six hours later, a qPCR analysis to determine the mRNA levels of the IFNB1 gene was performed. The results are shown as the inhibition rate (%).
-
Nat Commun
An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression. [Abstract]2026 Jan 21;17(1):1902. PMID: 41565660
Ravoxertinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 21;17(1):1902. [Abstract]
U87, U251, and H1299 cells, with or without EGFR R252C mutation were treated with or without 5 μM Ravoxertinib. Cell proliferation was assessed at day 7. Relative proliferation was calculated using vehicle-treated EGFR WT cells as the control.
-
Nat Commun
IGF1R-phosphorylated PYCR1 facilitates ELK4 transcriptional activity and sustains tumor growth under hypoxia. [Abstract]2023 Sep 30;14(1):6117. PMID: 37777542
Ravoxertinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Sep 30;14(1):6117. [Abstract]
HCT116 cells were pretreated with PPP (1 μM), ARQ-092 (2 μM) and GDC-0994 (Ravoxertinib, 10 μM) for 1 h before being cultured under hypoxia for 12 h.
-
Sci Transl Med
A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. [Abstract]2021 Jan 27;13(578):eaba7308. PMID: 33504651 -
Nucleic Acids Res
CFIm-mediated alternative polyadenylation remodels cellular signaling and miRNA biogenesis. [Abstract]2022 Apr 8;50(6):3096-3114. PMID: 35234914 -
J Exp Clin Cancer Res
Pulmonary interleukin 1 beta/serum amyloid A3 axis promotes lung metastasis of hepatocellular carcinoma by facilitating the pre-metastatic niche formation. [Abstract]2023 Jul 13;42(1):166. PMID: 37443052
Ravoxertinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 Jul 13;42(1):166. [Abstract]
The effect of NF-κB, ERK, JNK and p38 inhibitors on IL-1β-induced Saa3 expression in vivo. One hour after intravenous administration of Ravoxertinib, IL-1β (20 ng in 100 ul saline) were i.v. administrated into the mice. Six hours later, lung Saa3 expression was detected by qPCR.
Ravoxertinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 Jul 13;42(1):166. [Abstract]
The effect of NF-κB, ERK, JNK and p38 inhibitors on IL-1β-induced Saa3 expression in MLE-12 cells. MLE-12 cells were pre-treated with Ravoxertinib for 1 h, then stimulated with IL-1β (10 ng/ml) for 6 h. Saa3 expression was detected by qPCR.
-
Cell Discov
ASCT2 palmitoylation regulated by JNK1-ZDHHC14 axis orchestrates glutamine metabolism and NSCLC progression. [Abstract]2026 Feb 24;12(1):13. PMID: 41730846 -
Redox Biol
2023 Sep:65:102825. PMID: 37531930 -
Cell Rep Med
2025 Feb 6:101970. PMID: 39938523 -
Cell Death Dis
Targeting SYK of monocyte-derived macrophages regulates liver fibrosis via crosstalking with Erk/Hif1α and remodeling liver inflammatory environment. [Abstract]2021 Dec 1;12(12):1123. PMID: 34853322 -
Diabetes
Cardiac Tissue Factor Regulates Inflammation, Hypertrophy, and Heart Failure in Mouse Model of Type 1 Diabetes. [Abstract]2021 Sep;70(9):2131-2146. PMID: 34155039 -
Stem Cell Res Ther
Interleukin-1 receptor antagonist overexpression in mesenchymal stem cells improves hemorrhagic cystitis outcomes via HtrA serine peptidase 3. [Abstract]2025 Jul 1;16(1):337. PMID: 40598340 -
Oncogene
2021 Jul;40(30):4884-4893. PMID: 34163029 -
Environ Pollut
BPA modulates the WDR5/TET2 complex to regulate ERβ expression in eutopic endometrium and drives the development of endometriosis. [Abstract]2021 Jan 1;268(Pt B):115748. PMID: 33022573 -
Cell Rep
2023 Sep 1;42(9):113048. PMID: 37659078 -
Clin Transl Med
Regulatory roles of Osteopontin in lung epithelial inflammation and epithelial-telocyte interaction. [Abstract]2023 Aug;13(8):e1381. PMID: 37605313 -
Neural Regen Res
Overexpression of mitogen-activated protein kinase phosphatase-1 in endothelial cells reduces blood-brain barrier injury in a mouse model of ischemic stroke. [Abstract]2023 Aug;18(8):1743-1749. PMID: 36751800 -
Biochem Pharmacol
Molecular Dissection of the AHR-AREG driven EGFR-ERK1/2-CyclinD1 axis in acquired lenvatinib resistance of Hepatocellular carcinoma. [Abstract]2025 Jun 6:239:117032. PMID: 40482839 -
Gastric Cancer
2023 May;26(3):379-392. PMID: 36811690 -
Cancer
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. [Abstract]2020 Mar 15;126(6):1339-1350. PMID: 31821539 -
Int Immunopharmacol
TMEM176A drives anti-apoptotic signaling through TGM2-mediated ERK activation in gastric cancer. [Abstract]2025 Nov 8;168(Pt 1):115798. PMID: 41207103 -
Invest Ophthalmol Vis Sci
Hyperglycemia-Reduced Platelet-Derived Growth Factor-BB Expression Impairs Corneal Wound Healing in Diabetic Mice. [Abstract]2025 Aug 1;66(11):61. PMID: 40856651 -
Zool Res
Production of functional sperm from in vitro-cultured premeiotic spermatogonia in a marine fish. [Abstract]2022 Jul 18;43(4):537-551. PMID: 35616259 -
Mol Oncol
Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment. [Abstract]2020 Nov;14(11):2894-2919. PMID: 33021054 -
Cancers (Basel)
Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening. [Abstract]2022 Mar 19;14(6):1575. PMID: 35326726 -
Cancers (Basel)
RON ( MST1R) and HGFL ( MST1) Co-Overexpression Supports Breast Tumorigenesis through Autocrine and Paracrine Cellular Crosstalk. [Abstract]2022 May 19;14(10):2493. PMID: 35626096 -
ACS Omega
Ravoxertinib Improves Long-Term Neurologic Deficits after Experimental Subarachnoid Hemorrhage through Early Inhibition of Erk1/2. [Abstract]2023 May 23;8(22):19692-19704. PMID: 37305289 -
J Cell Mol Med
CXXC finger protein 4 inhibits the CDK18-ERK1/2 axis to suppress the immune escape of gastric cancer cells with involvement of ELK1/MIR100HG pathway. [Abstract]2020 Sep;24(17):10151-10165. PMID: 32715641 -
iScience
2024 Sep 12;27(10):110873. PMID: 39398235 -
Am J Physiol Heart Circ Physiol
Overexpression of the neuronal human (pro)renin receptor mediates angiotensin II-independent blood pressure regulation in the central nervous system. [Abstract]2018 Mar 1;314(3):H580-H592. PMID: 29350998 -
Proteomics
A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells. [Abstract]2023 Aug;23(16):e2300041. PMID: 37140101 -
J Pharmacol Exp Ther
2020 Jul;374(1):104-112. PMID: 32434944 -
Cell Signal
2023 May:105:110607. PMID: 36690134 -
Exp Mol Pathol
Up-regulation of miRNA-151-3p enhanced the neuroprotective effect of dexmedetomidine against β-amyloid by targeting DAPK-1 and TP53. [Abstract]2021 Feb;118:104587. PMID: 33275947 -
Int J Med Sci
The Fgl2 interaction with Tyrobp promotes the proliferation of cutaneous squamous cell carcinoma by regulating ERK-dependent autophagy. [Abstract]2022 Jan 1;19(1):195-204. PMID: 34975313 -
Pathol Res Pract
EPB41L5 promotes EMT through the ERK/p38 MAPK signaling pathway in esophageal squamous cell carcinoma. [Abstract]2021 Dec:228:153682. PMID: 34784520 -
Am J Cancer Res
ERRα promotes pancreatic cancer progression by enhancing the transcription of PAI1 and activating the MEK/ERK pathway. [Abstract]2020 Nov 1;10(11):3622-3643. PMID: 33294258 -
J Cell Biochem
Vascular endothelial growth factor enhances tendon-bone healing by activating Yes-associated protein for angiogenesis induction and rotator cuff reconstruction in rats. [Abstract]2020 Mar;121(3):2343-2353. PMID: 31633245 -
Toxicol In Vitro
Combined SRPK and AKT pharmacological inhibition is synergistic in T-cell acute lymphoblastic leukemia cells. [Abstract]2020 Jun;65:104777. PMID: 31962201 -
Reprod Sci
Bisphenol A Exposure Enhances Endometrial Stromal Cell Invasion and Has a Positive Association with Peritoneal Endometriosis. [Abstract]2020 Feb;27(2):704-712. PMID: 32046440 -
Biochem Biophys Rep
2026 Jan 15:45:102454. PMID: 41584303 -
Biochem Biophys Res Commun
MAL2 interacts with IQGAP1 to promote pancreatic cancer progression by increasing ERK1/2 phosphorylation. [Abstract]2021 May 21:554:63-70. PMID: 33780861 -
-
-
-
ACS Comb Sci
Benzimidazolyl-pyrazolo[3,4- b]pyridinones, Selective Inhibitors of MOLT-4 Leukemia Cell Growth and Sea Urchin Embryo Spiculogenesis: Target Quest. [Abstract]2019 Dec 9;21(12):805-816. PMID: 31689077 -
Methods Mol Biol
2018:1711:351-398. PMID: 29344898
Lösungsmittel & Löslichkeit
DMSO : ≥ 35 mg/mL (79.39 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (3.79 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.67 mg/mL (3.79 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
Mice[1]
PK/PD data for Ravoxertinib (GDC-0994) in the HCT116 mouse xenograft model. HCT116 tumors are established in nude mice to a tumor volume of 400-600 mm3. Mice are treated with a single oral dose of 22 at 15, 30, or 100 mg/kg versus vehicle control alone (40% PEG400/60% (10% HPβCD)) follow by tumor and plasma collection at 2, 8, 16, and 24 h postdose. Tumor levels of phosphorylated p90RSK (pRSK) relative total p90RSK (tRSK) are measured by quantitative Western blot and are normalized to vehicle control at 2 h postdose (set to 100%). Plasma and tumor concentrations are measured by LC−MS.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2683 mL | 11.3415 mL | 22.6829 mL | 56.7073 mL |
| 5 mM | 0.4537 mL | 2.2683 mL | 4.5366 mL | 11.3415 mL | |
| 10 mM | 0.2268 mL | 1.1341 mL | 2.2683 mL | 5.6707 mL | |
| 15 mM | 0.1512 mL | 0.7561 mL | 1.5122 mL | 3.7805 mL | |
| 20 mM | 0.1134 mL | 0.5671 mL | 1.1341 mL | 2.8354 mL | |
| 25 mM | 0.0907 mL | 0.4537 mL | 0.9073 mL | 2.2683 mL | |
| 30 mM | 0.0756 mL | 0.3780 mL | 0.7561 mL | 1.8902 mL | |
| 40 mM | 0.0567 mL | 0.2835 mL | 0.5671 mL | 1.4177 mL | |
| 50 mM | 0.0454 mL | 0.2268 mL | 0.4537 mL | 1.1341 mL | |
| 60 mM | 0.0378 mL | 0.1890 mL | 0.3780 mL | 0.9451 mL |